Clinical trials
Ovarian Neoplasms trials in China with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
110 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2015 | 6 |
| 2017 | 7 |
| 2018 | 8 |
| 2019 | 7 |
| 2020 | 13 |
| 2021 | 16 |
| 2022 | 24 |
| 2023 | 16 |
| 2024 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 110 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 7 |
| Peking Union Medical College Hospital | 6 |
| Lei Li | 5 |
| Xiaoxiang Chen | 5 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 4 |
| Chongqing University Cancer Hospital | 3 |
| Hunan Cancer Hospital | 3 |
| Jiangsu HengRui Medicine Co., Ltd. | 3 |
| Sun Yat-sen University | 3 |
| Chinese PLA General Hospital | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ovarian Neoplasms | 110 |
| Uterine Cervical Neoplasms | 15 |
| Endometrial Neoplasms | 12 |
| Pancreatic Neoplasms | 9 |
| Breast Neoplasms | 8 |
| Carcinoma, Ovarian Epithelial | 8 |
| Fallopian Tube Neoplasms | 8 |
| Lung Neoplasms | 8 |
| Colorectal Neoplasms | 7 |
| Neoplasms | 7 |
Trials
Showing 1 to 25 of 110. Each trial links to its page on Pharma Observatory.
10 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.